An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells

Expert Opinion on Biological Therapy

Volumn 14, Issue 7, 2014, Pages 905-916

  Jäkel, Clara E ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Adoptive immunotherapy; Cytokine induced killer cells; Dendritic cells; NKT cells; Solid tumors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ONCOLYTIC VIRUS; CYTOKINE;

ADOPTIVE IMMUNOTHERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DENDRITIC CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMALLY INVASIVE PROCEDURE; MULTIMODALITY CANCER THERAPY; NONHUMAN; REVIEW; SOLID TUMOR; ANIMAL; NEOPLASMS; PROCEDURES; TRANSPLANTATION;

ANGIOGENESIS INHIBITORS; ANIMALS; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; IN VITRO TECHNIQUES; NEOPLASMS; ONCOLYTIC VIRUSES;

EID: 84902157972     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.900537     Document Type: Review

References (67)

1. Lopez RD, Waller EK, Lu PH, Negrin RS. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother 2001; 49(12): 629-40
2. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174(1):139-49
3. Ochoa AC, Gromo G, Alter BJ, et al. Long-term growth of lymphokineactivated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol 1987;138(8):2728-33
4. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21(13):1673-9
5. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153(4):1687-96
6. Sangiolo D, Martinuzzi E, Todorovic M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008;20(7):841-8
7. Franceschetti M, Pievani A, Borleri G, et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009;37(5):616-28
8. Verneris MR, Ito M, Baker J, et al. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001;7(10):532-42
9. Verneris MR, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004;103(8):3065-72
10. Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96(12):6879-84
11. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62(21):6178-86
12. Chen Y, Lin G, Guo ZQ, et al. Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PLoS ONE 2013;8(7):e69044
13. Pan K, Wang QJ, Liu Q, et al. The phenotype of ex vivo generated cytokineinduced killer cells is associated with overall survival in patients with cancer. Tumour Biol 2014;35(1):701-7
14. Gammaitoni L, Giraudo L, Leuci V, et al. Effective activity of cytokineinduced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res 2013;19(16):4347-58
15. Sangiolo D, Mesiano G, Gammaitoni L, et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Cancer Res 2013;74(1):1-11
16. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414(6859):105-11
17. Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012;12(5):565-72
18. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441(7090):235-8
19. Lin G, Wang J, Lao X, et al. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother 2012;35(4):337-43
20. Zoll B, Lefterova P, Csipai M, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 1998;47(4):221-6
21. Helms MW, Prescher JA, Cao YA, et al. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010;59(9):1325-34
22. Rettinger E, Kuc?i S, Naumann I, et al. The cytotoxic potential of interleukin-15-stimulated cytokineinduced killer cells against leukemia cells. Cytotherapy 2012;14(1):91-103
23. Rettinger E, Meyer V, Kreyenberg H, et al. Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models. Front Oncol 2012;2:32
24. Tao Q, Chen T, Tao L, et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3 +CD56+ cells and downregulating regulatory T cells as well as IL-35. J Immunother 2013;36(9):462-7
25. Wei C, Wang W, Pang W, et al. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma. Tumour Biol 2013; Epub ahead of print
26. Cai C, Chen W, Miao D, et al. Toll-like receptor 4 is required for the cytotoxicity of cytokine-induced killer cells. Acta Haematol 2013;132(1)
27. Zhao N, Zhao MF, Rajbhandary S, et al. Effects of humanized interleukin 21 on anti-leukemic activity of cytokine induced killer cells and the mechanism. Zhonghua Xue Ye Xue Za Zhi 2012;33(10):823-8
28. Rajbhandary S, Zhao MF, Zhao N, et al. Multiple Cytotoxic Factors Involved in IL-21 Enhanced Antitumor Function of CIK Cells Signaled through STAT-3 and STAT5b Pathways. Asian Pac J Cancer Prev 2013;14(10):5825-31
29. Yan Y, Xu Y, Zhao Y, et al. Combination of E2F-1 promoterregulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model. Tumour Biol 2013. [Epub ahead of print]
30. Yang Z, Zhang Q, Xu K, et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One 2012; 7(9): e44802
31. Liu C, Suksanpaisan L, Chen YW, et al. Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol 2013;41(6):508-17
32. Ong HT, Hasegawa K, Dietz AB, et al. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007;14:324-33
33. Märten A, Ziske C, Schöttker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001;24(6):502-10
34. Cui Y, Yang X, Zhu W, et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett 2013;6(2):537-41
35. Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IG. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res 2011;35(9):1136-42.
36. Wang YF, Kunda PE, Lin JW, et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. Oncol Rep 2013;29(5):1841-50
37. Wongkajornsilp A, Wamanuttajinda V, Kasetsinsombat K, et al. Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3(+)CD56(+) subset through the co-culturing dendritic cells. PLoS One 2013;8(11):e78980
38. Chen J, Huang X, Huang G, et al. Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother Radiopharm 2012;27(3):210-20
39. Liu Q, Wang Y, Wang H, et al. Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol 2013;139(8):1357-72
40. Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 2013;62(1):65-73
41. Shi SB, Ma TH, Li CH, Tang XY. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 2012;98(3):314-19
42. Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 2013. [Epub ahead of print]
43. Zhan HL, Gao X, Pu XY, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl) 2012; 125(21): 3771-7
44. Qiu Y, Xu MB, Yun MM, et al. Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J Gastroenterol 2011;17(48):5260-6
45. Qiu Y, Yun MM, Xu MB, et al. Pancreatic carcinoma-specific immunotherapy using synthesised alphagalactosyl epitope-activated immune responders: findings from a pilot study. Int J Clin Oncol 2013;18(4):657-65
46. Du X, Jin R, Ning N, et al. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep 2012;28(5):1743-9
47. Zhang L, Hou Y, Zhang J, et al. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett 2013;5(6):1826-32
48. Huang J, Li C, Wang Y, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol 2013;149(1):156-68
49. Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012;2012:238924
50. Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol Ther 2013;21(12):2268-77
51. Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS ONE 2013;8(6):e65757
52. Tao L, Huang G, Shi S, Chen L. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol 2014;31(1):777
53. Wang JP, Li W, Huang ZL, et al. Value of CIK in the treatment of TACE combined with RFA for HCC in long-term survival and prognostic analysis. Zhonghua Yi Xue Za Zhi 2012;92(43):3062-6
54. Huang ZM, Li W, Li S, et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother 2013;36(5):287-93
55. Niu LZ, Li JL, Zeng JY, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol 2013;19(22):3473-80
56. Yuanying Y, Lizhi N, Feng M, et al. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology 2013;67(2):235-40
57. Wang Z, Zhang Y, Liu Y, et al. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. J Immunother 2014;37(1):43-50
58. Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokineinduced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 2012;61(12):2251-9
59. Zhao H, Fan Y, Li H, et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother Radiopharm 2013;28(4):303-9
60. Liu H, Song J, Yang Z, Zhang X. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med 2013;6(4):953-6
61. Pan K, Li YQ, Wang W, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol 2013;20(13):4305-11
62. Yu X, Zhao H, Liu L, et al. A randomized phase II study of autologous cytokineinduced killer cells in treatment of hepatocelluar carcinoma. J Clin Immunol 2013. [Epub ahead of print]
63. Li R, Wang C, Liu L, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 2012; 61(11): 2125-33
64. Zhu Y, Zhang H, Li Y, et al. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunol Immunother 2013;62(10):1629-35
65. Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012;18(6):1751-9
66. Liang XF,MaDC, Ding ZY, et al. Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study. Zhonghua Zhong Liu Za Zhi 2013;35(10):764-8
67. Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137(2):305-10